Report cover image

Amyotrophic Lateral Sclerosis - Global Clinical Trials Review, 2025

Publisher GlobalData
Published Jul 30, 2025
Length 543 Pages
SKU # GBDT20326619

Description

Amyotrophic Lateral Sclerosis - Global Clinical Trials Review, 2025

Summary

GlobalData's clinical trial report, “Amyotrophic Lateral Sclerosis - Global Clinical Trials Review, 2025 provides an overview of Amyotrophic Lateral Sclerosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

543 Pages
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Amyotrophic Lateral Sclerosis
Jul 28, 2025: Xellsmart Completed World’s First Patient Dosing in Its Registrational Clinical Trial for iPSC-Derived Subtype-Specific Neural Cell Therapy for SCI
Jul 24, 2025: AB Science Has Received Approval From Several European Countries To Initiate the Confirmatory Phase 3 Study of Masitinib in ALS
Jul 09, 2025: Transposon Receives Investment from the Alzheimer's Drug Discovery Foundation to Support Advancement of TPN-101 for the Treatment of AD
Jul 08, 2025: FDA Review of Citizen Petition Offers a Fresh Look at NurOwn’s Evidence of Treatment Effectiveness
Jun 23, 2025: Mitsubishi Tanabe Pharma America Marks Three Years Since Launch of RADICAVA ORS (edaravone) in the U.S.
Jun 20, 2025: Neurizon : Verification of Significant Blood-Brain Barrier Penetration of NUZ-001
Jun 05, 2025: Corcept Presents Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
May 29, 2025: Neuronata-R Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval
May 28, 2025: Transposon Announces TPN-101 in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS
May 28, 2025: Zydus Receives USFDA ‘Fast Track Designation’ for Usnoflast, a Novel Oral NLRP3 inhibitor, for the treatment of Amyotrophic Lateral Sclerosis
May 19, 2025: BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn for ALS
May 15, 2025: Arbor Biotechnologies to Present Data on CNS Programs and Platform Advances at the ASGCT 28th Annual Meeting
May 14, 2025: Neurizon to Present at 4th Annual ALS Drug Development Summit
May 13, 2025: Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
May 12, 2025: MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
May 07, 2025: Vectory Therapeutics To Present Preclinical Data on Novel ALS Therapeutic Strategy at Target ALS Conference in Boston
May 05, 2025: AB Science Will Present New Data From Masitinib Clinical Program in ALS in Two Presentations at the 2025 Encals Annual Meeting
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Source
List of Tables
Table 1: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Region, 2025*
Table 2: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
Table 3: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
Table 4: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2025*
Table 5: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2025*
Table 6: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, North America, Top Countries, 2025*
Table 7: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2025*
Table 8: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2025*
Table 9: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2025*
Table 10: Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
Table 11: Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
Table 12: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2025*
Table 13: Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
Table 14: Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
Table 15: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase, 2025*
Table 16: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2025*
Table 17: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2025*
Table 18: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2025*
Table 19: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
Table 20: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2025*
Table 21: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
Table 22: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
Table 23: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
List of Figures
Figure 1: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Region (%), 2025*
Figure 2: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
Figure 3: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
Figure 4: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2025*
Figure 5: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2025*
Figure 6: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2025*
Figure 7: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2025*
Figure 8: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2025*
Figure 9: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2025*
Figure 10: Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
Figure 11: Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
Figure 12: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2025*
Figure 13: Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
Figure 14: Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
Figure 15: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2025*
Figure 16: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2025*
Figure 17: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2025*
Figure 18: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2025*
Figure 19: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
Figure 20: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2025*
Figure 21: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
Figure 22: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
Figure 23: Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
Figure 24: GlobalData Methodology

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us